[HTML][HTML] Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
…, MM Rajah, C Planchais, F Porrot, N Robillard… - Nature, 2021 - nature.com
The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1 , 2 , 3 , 4 – 5 .
Since then, it has become dominant in some regions of India and in the UK, and has spread to …
Since then, it has become dominant in some regions of India and in the UK, and has spread to …
Reduced sensitivity of infectious SARS-CoV-2 variant B. 1.617. 2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
…, MM Rajah, C Planchais, F Porrot, N Robillard… - Biorxiv, 2021 - biorxiv.org
The SARS-CoV-2 B.1.617 lineage emerged in October 2020 in India 1 – 6 . It has since then
become dominant in some indian regions and further spread to many countries. The …
become dominant in some indian regions and further spread to many countries. The …
[PDF][PDF] Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value
…, S Kernéis, G Poulet, M Wack, N Robillard… - Clin Infect …, 2020 - stillatechnologies.com
… David Veyer 1,2, Solen Kernéis 3,4,5, Geoffroy Poulet 6, Maxime Wack7,8, Nicolas
Robillard 1, Valérie Taly 5, Anne-Sophie L’Honneur9, Flore Rozenberg9, Pierre Laurent-Puig …
Robillard 1, Valérie Taly 5, Anne-Sophie L’Honneur9, Flore Rozenberg9, Pierre Laurent-Puig …
Highly sensitive quantification of plasma severe acute respiratory syndrome coronavirus 2 RNA sheds light on its potential clinical value
…, G Poulet, M Wack, N Robillard… - Clinical Infectious …, 2021 - academic.oup.com
Background Coronavirus disease 2019 (COVID-19) is a global public health problem that has
already caused more than 662 000 deaths worldwide. Although the clinical manifestations …
already caused more than 662 000 deaths worldwide. Although the clinical manifestations …
[HTML][HTML] Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational …
Background The dynamics of SARS-CoV-2 alpha variant shedding and immune responses
at the nasal mucosa remain poorly characterised. Methods We measured infectious viral …
at the nasal mucosa remain poorly characterised. Methods We measured infectious viral …
[HTML][HTML] Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY. 4.2
…, F Porrot, D Veyer, H Péré, N Robillard… - …, 2022 - thelancet.com
Background SARS-CoV-2 lineages are continuously evolving. As of December 2021, the AY.4.2
Delta sub-lineage represented 20 % of sequenced strains in the UK and had been …
Delta sub-lineage represented 20 % of sequenced strains in the UK and had been …
Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19
…, B Védie, T Bruel, E Tartour, N Robillard… - Clinical Infectious …, 2021 - pasteur.hal.science
Background: Humoral response to SARS-CoV-2 occurs within the first weeks after COVID-19.
Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution …
Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution …
Sera neutralizing activities against severe acute respiratory syndrome coronavirus 2 and multiple variants 6 months after hospitalization for coronavirus disease 2019
…, B Védie, T Bruel, E Tartour, N Robillard… - Clinical Infectious …, 2021 - academic.oup.com
Background Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those …
occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those …
[HTML][HTML] Usefulness of plasma SARS-CoV-2 RNA quantification by droplet-based digital PCR to monitor treatment against COVID-19 in a B-cell lymphoma patient
TA Szwebel, D Veyer, N Robillard, D Eshagh… - Stem Cell Reviews and …, 2021 - Springer
We report the case of an HIV-1-infected patient, treated with anti-CD20 monoclonal antibody
for a B-cell lymphoma previously treated by autologous stem cell transplant. He suffered …
for a B-cell lymphoma previously treated by autologous stem cell transplant. He suffered …
[HTML][HTML] Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab
…, H Péré, J Fourgeaud, L Amrouche, N Robillard… - American Journal of …, 2022 - Elsevier
Immunocompromised patients may experience prolonged viral shedding after their initial
SARS-CoV-2 infection, however, symptomatic relapses after remission currently remain rare. …
SARS-CoV-2 infection, however, symptomatic relapses after remission currently remain rare. …